Press release
Psychosis in Parkinson's Disease and Alzheimer's Disease Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Sunovion Pharma, Merck, Vanda Pharma, Intra-Cellular Therapeutics
To Know in detail about the Psychosis in Parkinson's Disease and Alzheimer's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Psychosis in Parkinson's Disease and Alzheimer's Disease Market Forecast
https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Psychosis in Parkinson's Disease and Alzheimer's Disease Market Report:
• The Psychosis in Parkinson's Disease and Alzheimer's Disease market size was valued approximately USD 1,290 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2023, the market size for psychosis associated with Parkinson's disease and Alzheimer's disease in the US was around USD 868 million. This figure is expected to grow, driven by rising disease awareness and advancements in treatment options.
• In 2023, the total market size for the EU4 and the UK was estimated at approximately USD 219 million, representing nearly 17% of the total market revenue for the 7MM.
• In 2023, within the EU4 and the UK, Germany had the largest market share, valued at approximately USD 71 million, followed by the UK at USD 23 million, and Italy at USD 39 million.
• In 2023, NUPLAZID held the largest market share among therapies currently used in the US, generating approximately USD 562 million in revenue.
• In 2023, the total number of diagnosed prevalent cases of Parkinson's disease in the 7MM was estimated at 2.6 million. The US represented about 45% of these cases, while the EU4 and the UK together also accounted for 45%, and Japan contributed 10%. This number of cases is projected to rise by 2034.
• Within the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases of Parkinson's disease, totaling 487,000, followed by France with 223,000 cases. Spain had the lowest number, with 150,000 cases in 2023.
• In 2023, the total diagnosed prevalent cases of Alzheimer's disease in the US reached 6.3 million, and these numbers are projected to fluctuate during the forecast period.
• Estimates from DelveInsight's epidemiology model indicate that in 2023, the age-specific cases of Parkinson's disease in the EU4 and the UK were approximately 18,000 for those under 50, 62,000 for the 50-59 age group, 338,000 for those aged 60-69, and 773,000 for individuals aged 70 and older.
• DelveInsight's analysis found that Japan had 2.1 million diagnosed prevalent cases of Alzheimer's disease psychosis in 2023, with this figure projected to increase at a CAGR of 1.9% by 2034.
• Key Psychosis in Parkinson's Disease and Alzheimer's Disease Companies: Acadia Pharmaceuticals, Karuna Therapeutics, Sunovion Pharmaceuticals, Vanda Pharmaceuticals, Intra-Cellular Therapeutics, Merck Sharp & Dohme, and others
• Key Psychosis in Parkinson's Disease and Alzheimer's Disease Therapies: NUPLAZID (pimavanserin), KarXT, Ulotaront, FANAPT, ITI-1284, MK-8189, and others
• The Parkinson's Disease epidemiology based on gender analyzed that in the US, males diagnosed with PD are higher in number than females
• The Psychosis in Parkinson's Disease and Alzheimer's Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Psychosis in Parkinson's Disease and Alzheimer's Disease pipeline products will significantly revolutionize the Psychosis in Parkinson's Disease and Alzheimer's Disease market dynamics.
Psychosis in Parkinson's Disease and Alzheimer's Disease Overview
The National Institute of Mental Health (NIMH) defines psychosis as a group of symptoms affecting the mind in which there has been a partial loss of reality awareness. People have disruptions in their thoughts and perceptions during a psychotic episode, making it difficult for them to distinguish between reality and illusion.
In Parkinson's disease (PD) and Alzheimer's disease (AD), psychosis develops as a result of both endogenous (associated with the disease process) and exogenous (drugs, for example).
Get a Free sample for the Psychosis in Parkinson's Disease and Alzheimer's Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Psychosis in Parkinson's Disease and Alzheimer's Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Psychosis in Parkinson's Disease and Alzheimer's Disease Epidemiology Segmentation:
The Psychosis in Parkinson's Disease and Alzheimer's Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Psychosis in Parkinson's Disease and Alzheimer's Disease
• Prevalent Cases of Psychosis in Parkinson's Disease and Alzheimer's Disease by severity
• Gender-specific Prevalence of Psychosis in Parkinson's Disease and Alzheimer's Disease
• Diagnosed Cases of Episodic and Chronic Psychosis in Parkinson's Disease and Alzheimer's Disease
Download the report to understand which factors are driving Psychosis in Parkinson's Disease and Alzheimer's Disease epidemiology trends @ Psychosis in Parkinson's Disease and Alzheimer's Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Psychosis in Parkinson's Disease and Alzheimer's Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psychosis in Parkinson's Disease and Alzheimer's Disease market or expected to get launched during the study period. The analysis covers Psychosis in Parkinson's Disease and Alzheimer's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Psychosis in Parkinson's Disease and Alzheimer's Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Psychosis in Parkinson's Disease and Alzheimer's Disease Therapies and Key Companies
• NUPLAZID (pimavanserin): Acadia Pharmaceuticals
• KarXT: Karuna Therapeutics
• Ulotaront: Sunovion Pharmaceuticals
• FANAPT: Vanda PharmaceuticalsF
• ITI-1284: Intra-Cellular Therapeutics
• MK-8189: Merck Sharp & Dohme
Discover more about therapies set to grab major Psychosis in Parkinson's Disease and Alzheimer's Disease market share @ Psychosis in Parkinson's Disease and Alzheimer's Disease Treatment Landscape
https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Psychosis in Parkinson's Disease and Alzheimer's Disease Market Strengths
• Increased awareness and a more in-depth understanding of the disease pathophysiology has improved diagnosis and treatment.
• The recent US FDA approval of NUPLAZID, the first approved therapy for treating hallucinations and delusions associated with PD Psychosis, indicates a positive change in treatment paradigm.
Psychosis in Parkinson's Disease and Alzheimer's Disease Market Opportunities
• There are opportunities for pharma players to develop therapies with improved safety and tolerability profiles, effectively reducing symptoms and preventing the recurrence of Psychosis in PD and AD.
• Advancement in biomarkers for cognitive decline allows precise diagnosis and individualized treatments
Scope of the Psychosis in Parkinson's Disease and Alzheimer's Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Psychosis in Parkinson's Disease and Alzheimer's Disease Companies: Acadia Pharmaceuticals, Karuna Therapeutics, Sunovion Pharmaceuticals, Vanda Pharmaceuticals, Intra-Cellular Therapeutics, Merck Sharp & Dohme, and others
• Key Psychosis in Parkinson's Disease and Alzheimer's Disease Therapies: NUPLAZID (pimavanserin), KarXT, Ulotaront, FANAPT, ITI-1284, MK-8189, and others
• Psychosis in Parkinson's Disease and Alzheimer's Disease Therapeutic Assessment: Psychosis in Parkinson's Disease and Alzheimer's Disease current marketed and Psychosis in Parkinson's Disease and Alzheimer's Disease emerging therapies
• Psychosis in Parkinson's Disease and Alzheimer's Disease Market Dynamics: Psychosis in Parkinson's Disease and Alzheimer's Disease market drivers and Psychosis in Parkinson's Disease and Alzheimer's Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Psychosis in Parkinson's Disease and Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Psychosis in Parkinson's Disease and Alzheimer's Disease Market Access and Reimbursement
To know more about Psychosis in Parkinson's Disease and Alzheimer's Disease companies working in the treatment market, visit @ Psychosis in Parkinson's Disease and Alzheimer's Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Psychosis in Parkinson's Disease and Alzheimer's Disease Market Report Introduction
2. Executive Summary for Psychosis in Parkinson's Disease and Alzheimer's Disease
3. SWOT analysis of Psychosis in Parkinson's Disease and Alzheimer's Disease
4. Psychosis in Parkinson's Disease and Alzheimer's Disease Patient Share (%) Overview at a Glance
5. Psychosis in Parkinson's Disease and Alzheimer's Disease Market Overview at a Glance
6. Psychosis in Parkinson's Disease and Alzheimer's Disease Disease Background and Overview
7. Psychosis in Parkinson's Disease and Alzheimer's Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Psychosis in Parkinson's Disease and Alzheimer's Disease
9. Psychosis in Parkinson's Disease and Alzheimer's Disease Current Treatment and Medical Practices
10. Psychosis in Parkinson's Disease and Alzheimer's Disease Unmet Needs
11. Psychosis in Parkinson's Disease and Alzheimer's Disease Emerging Therapies
12. Psychosis in Parkinson's Disease and Alzheimer's Disease Market Outlook
13. Country-Wise Psychosis in Parkinson's Disease and Alzheimer's Disease Market Analysis (2020-2034)
14. Psychosis in Parkinson's Disease and Alzheimer's Disease Market Access and Reimbursement of Therapies
15. Psychosis in Parkinson's Disease and Alzheimer's Disease Market Drivers
16. Psychosis in Parkinson's Disease and Alzheimer's Disease Market Barriers
17. Psychosis in Parkinson's Disease and Alzheimer's Disease Appendix
18. Psychosis in Parkinson's Disease and Alzheimer's Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Psychosis in Parkinson's Disease and Alzheimer's Disease Epidemiology https://www.delveinsight.com/report-store/psychosis-in-parkinsons-and-alzheimers-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Psychosis in Parkinson's Disease and Alzheimer's Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Psychosis in Parkinson's Disease and Alzheimer's Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Egfr-induced Skin Disorders Market
https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market
DelveInsight's "EGFR Inhibitors-Induced Skin Disorders Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of EGFR Inhibitors-Induced Skin Disorders, historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Endometrial Cancer Market
https://www.delveinsight.com/report-store/endometrial-cancer-market
DelveInsight's "Endometrial Cancer Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Endometrial Cancer, historical and forecasted epidemiology as well as the Endometrial Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom and Japan.
Fragile X Syndrome Market
https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market
DelveInsight's "Fragile X Syndrome (FXS) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Fragile X Syndrome (FXS), historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432,
State: Las Vegas NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psychosis in Parkinson's Disease and Alzheimer's Disease Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Sunovion Pharma, Merck, Vanda Pharma, Intra-Cellular Therapeutics here
News-ID: 3661463 • Views: …
More Releases from DelveIinsight Business Research
Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, …
DelveInsight's "Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Advanced Renal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Advanced Renal…
PCSK9 Inhibitors Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, PCSK9 Inhibitors pipeline constitutes 14+ key companies continuously working towards developing 14+ PCSK9 Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"PCSK9 Inhibitors Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PCSK9 Inhibitors Market.
The PCSK9…
Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Prostate Cancer pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Metastatic Prostate Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Prostate…
Bunion (Hallux Valgus) Market to Expand Significantly by 2034, States DelveInsig …
DelveInsight's "Bunion Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bunion, historical and forecasted epidemiology as well as the Bunion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Bunion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bunion Market Forecast
https://www.delveinsight.com/sample-request/hallux-valgus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Bunion…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
